# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN-TD
- Date: 1948-05-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Mayfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five-week recovery review and second hepatitis B vaccine. **S**

## History of present illness

Ms. Holiday returns five weeks after starting buprenorphine, after a three-week tour. She has taken 16 mg every morning without a gap and has used no heroin or other opioids. Cravings are now brief and come mostly late at night after a show; she calls her peer recovery coach when they do. She takes acamprosate most days but sometimes forgets the midday dose. She has cut down to two or three drinks on performance nights. She spoke with her counselor by phone each week while away. Her mood is a little better. She kept the naloxone in her bag and has not needed it. **S**

| Element | Detail |
|---|---|
| Buprenorphine | 16 mg daily, no gaps |
| Opioid use | None |
| Cravings | Brief, late at night; she calls her peer coach |
| Alcohol | Two or three drinks on performance nights |
| Acamprosate | Most days; misses some midday doses |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | Constipation settled; no nausea |
| Psychiatric | Positive | Mood somewhat low at times; no thoughts of suicide or self-harm |
| Neurological | Negative | No tremor or unsteadiness |

3 systems reviewed. **S**

## Current medications

- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily **S**
- Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 **S**
- Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily **S**
- Thiamine 100 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 68.6 kg; BMI 25.2 kg/m². All vital signs are synthetic.

AST: 38 U/L; ALT: 30 U/L; GGT: 52 U/L (high); Phosphatidylethanol (PEth): 96 ng/mL (high); PHQ-9: 7. All results are synthetic.

## Change since baseline

- AST: 52 U/L (high) at baseline, 38 U/L at this visit **S**
- ALT: 38 U/L at baseline, 30 U/L at this visit **S**
- GGT: 84 U/L (high) at baseline, 52 U/L (high) at this visit **S**
- Phosphatidylethanol (PEth): 312 ng/mL (high) at baseline, 96 ng/mL (high) at this visit **S**
- PHQ-9: 9 at baseline, 7 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 118/76, pulse 74 |
| Abdomen | Soft and non-tender; no liver enlargement |
| Psychiatric | Engaged; no signs of intoxication or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder on buprenorphine** (F11.20). Stable on 16 mg with no opioid use; urine test shows buprenorphine only. The four-week gap since the one-week visit was longer than advised early in treatment, but weekly counseling calls continued and no harm resulted. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Continue buprenorphine with naloxone 16 mg daily.
   - Video check-ins every two weeks between visits while she tours.
2. **Alcohol use disorder on acamprosate** (F10.20). PEth down from 312 to 96 ng/mL: drinking reduced, not stopped. AST 38, ALT 30, GGT 52 U/L, all improving. PHQ-9 7. **S**
   - Continue acamprosate; take the midday dose with lunch, with a phone reminder.
   - Her goal for now is no more than two drinks on performance nights and none on other days.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, adherence, cravings, withdrawal, and side effects | Every visit | Completed today | 16 mg daily without gaps; brief cravings; no sedation |
| Self-management | Visit frequency | Every 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stable | Deferred | Four weeks since the one-week visit, longer than the one to two weeks advised in the first month, because she was on tour; the planned call-in visit at two weeks did not happen. Weekly counseling calls continued, and no harm resulted. Corrective action: video check-ins every two weeks between visits while touring |
| Laboratory | Urine drug testing, including fentanyl, explained as part of care rather than as a test of trust | At the start, then about monthly early in treatment and as needed | Completed today | Buprenorphine and norbuprenorphine only |
| Medication safety | Prescription drug monitoring program check | Before each buprenorphine prescription | Completed today | No other prescriptions |
| Medication safety | Naloxone at home and in her bag, and a trained companion | At the start; check and replace at each visit | Completed today | In her bag and at home; not used |
| Self-management | Overdose prevention: never using alone and fentanyl test strips | Every visit | Completed today | Reviewed |
| Self-management | Counseling and peer recovery support | Offered to everyone; not a condition of medication | Completed today | Weekly counseling by phone on tour; peer coach by phone |
| Survey | Drinking and PEth | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 96 ng/mL, from 312; two or three drinks on performance nights |
| Medication safety | Acamprosate adherence and kidney function | Kidney function before starting; adherence every visit | Completed today | Missing some midday doses; reminder set |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine daily |
| Laboratory | Liver tests (AST, ALT, GGT, albumin, bilirubin) | At intake, then every 1 to 3 months while drinking is heavy, and yearly | Completed today | AST 38, ALT 30, GGT 52 U/L, improving |
| Laboratory | FIB-4 fibrosis score | At intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 years | Up to date | 1.18 at intake; repeat at six months |
| Imaging | Vibration-controlled transient elastography | If FIB-4 is 1.3 or higher | Not indicated | FIB-4 below 1.3 |
| Self-management | Hepatitis A and B vaccines | Hepatitis B two doses 4 weeks apart; hepatitis A two doses 6 months apart | Completed today | Hepatitis B dose 2 given today; hepatitis A dose 2 at six months |
| Survey | Depression screen (PHQ-9) | At intake and at each recovery visit while symptoms are present | Completed today | PHQ-9 7, item 9 scored 0 |
| Survey | Suicide and overdose risk review, safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan and the 988 Suicide & Crisis Lifeline in her phone |

## Goal progress

- Stay on buprenorphine without interruption through six months, including through any return to use. In progress; target 1948-10-19. **S**
- Naloxone at home and in her bag, and a friend trained to use it, by the one-week visit. Outcome by 1948-04-27: Two naloxone two-packs dispensed; her friend trained. **S**
- Reduce drinking to PEth below 20 ng/mL, or to the level she chooses, by six months. In progress; target 1948-10-19. **S**
- Hepatitis A and B vaccine series completed by six months. In progress; target 1948-10-19. **S**
- PHQ-9 score below 5 by six months. In progress; target 1948-10-19. **S**

## Guideline basis

- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026), Substance Abuse and Mental Health Services Administration
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology)
- AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025), American Association for the Study of Liver Diseases (Hepatology)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Video check-ins every two weeks while touring. Three-month visit with PEth, liver tests, and the PHQ-9. **S**
- Next scheduled visit 1948-07-20: three-month review after a return to opioid use: adjusting the recovery plan. **S**
